Individualizing patient care in CML and MPNs
Why aren’t cytogenetic analyses being implemented into clinical studies of CLL?
Highlights from EHA 2016 press briefings: POLLUX and EURO-SKI trials and BiTE antibodies
Comparing ibrutinib efficacy and toxicity levels by age for patients with CLL/SLL
Genetic heterogeneity in AML: the reasoning behind targeting FLT3 and IDH